Supreme Pharmaceuticals Inc. Completes Shares for Debt Transaction

JULY 22, 2014

July 22, 2014, Vancouver, BC – Supreme Pharmaceuticals Inc. (“Supreme” or the “Company”) (SPRWD – OTC) (“SL” – CSE) announced that it has entered into Settlement Agreements with two creditors to settle debts owing to them by the issuance of a total of 652,500 common shares at a deemed issue price of $0.07 per share. Shares issued pursuant to this transaction will be subject to a hold period until November 24, 2014.

Contact Information

Investor Relations
430 – 580 Hornby Street, Vancouver BC
V6C 3B6
Phone: (647) 340-6744
Email: info@supreme.ca
Website: www.supreme.ca

FORWARD LOOKING INFORMATION

>This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the up grading of the facility, the timing on completetion of the MMPR License conditions and the start of production. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com and such factors as the Company failing to finish the upgrading of the facility and put the same into production in accordance within the terms of the MMPR license. This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995.